Skip to main
SMTI

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech is expected to see continued revenue growth and a reduction in net losses, driven by strong demand for its surgical soft tissue repair products, as well as potential future launches of new products or services. The company's cash and debt positions are relatively stable, providing sufficient capital for near-term operations. However, there are risks to achieving the 12-month price target, including potential obstacles to revenue growth and potential dilution risk. Overall, analysts recommend a Buy rating for the stock with a 12-month price target of $36 per share.

Bears say

Sanara MedTech is expected to see topline growth in the range of 13-17% in 2026, driven by the recent Vizient contract and the expected launch of OsStic bioadhesive. Despite the company's positive progress in securing contracts and expanding its product portfolio, its heavy reliance on new product launches for future growth and high levels of debt could pose risks to its financial stability. Additionally, negative market sentiment towards the overall medical technology industry could further impact the company's stock performance.

SMTI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Strong Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.